Valeo Pharma Inc
Valeo Pharma Inc. operates as a pharmaceutical company focused on licensing, acquiring, and commercializing drugs. The company provides commercialized pharmaceutical products in Canada, with a focus on respiratory/allergy, ophthalmology, and specialty therapeutic areas. It licenses and acquires Canadian rights to commercial-stage and proprietary drugs, managing registration and commercialization … Read more
Valeo Pharma Inc (VPHIF) - Total Liabilities
Latest total liabilities as of July 2024: $95.23 Million USD
Based on the latest financial reports, Valeo Pharma Inc (VPHIF) has total liabilities worth $95.23 Million USD as of July 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Valeo Pharma Inc - Total Liabilities Trend (2016–2023)
This chart illustrates how Valeo Pharma Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Valeo Pharma Inc Competitors by Total Liabilities
The table below lists competitors of Valeo Pharma Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
CFAGF
OTCGREY:CFAGF
|
USA | $2.46 Million |
|
DONGFENG MOTOR GP-H
MU:D4D
|
Germany | €171.07 Billion |
|
Wells Fargo & Company PFD DIV EQUALIZ
PINK:WFCNP
|
USA | $1.74 Trillion |
|
Bioventix
LSE:BVXP
|
UK | GBX1.31 Million |
|
Rocca SA
WAR:RCA
|
Poland | zł1.44 Million |
|
Entest Biomedical Inc
PINK:ETNI
|
USA | $50.66K |
Liability Composition Analysis (2016–2023)
This chart breaks down Valeo Pharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.51 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.96 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Valeo Pharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Valeo Pharma Inc (2016–2023)
The table below shows the annual total liabilities of Valeo Pharma Inc from 2016 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-10-31 | $81.54 Million | +7.14% |
| 2022-10-31 | $76.11 Million | +301.08% |
| 2021-10-31 | $18.98 Million | +140.40% |
| 2020-10-31 | $7.89 Million | +35.43% |
| 2019-10-31 | $5.83 Million | +22.64% |
| 2018-10-31 | $4.75 Million | -20.81% |
| 2017-10-31 | $6.00 Million | +81.65% |
| 2016-10-31 | $3.30 Million | -- |